Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 206, Issue 10, Pages 1504-1511Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis571
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases at the National Institutes of Health [U54 GM088491]
- National Institute of General Medical Sciences at the National Institutes of Health [2R01 GM080533-06]
- Canadian Institutes of Health Research
- GlaxoSmithKline
Ask authors/readers for more resources
A small proportion (1%-1.5%) of 2009 pandemic influenza A/H1N1 virus strains (A[H1N1]pdm09) are oseltamivir resistant, almost exclusively because of a H275Y mutation in the neuraminidase protein. However, many individuals infected with resistant strains had not received antivirals. Whether drug-resistant viruses are initially present as minor variants in untreated individuals before they emerge as the dominant strain in a virus population is of great importance for predicting the speed at which resistance will arise. To address this issue, we used ultra-deep sequencing of viral populations from serial nasopharyngeal specimens from an immunocompromised child and from 2 individuals in a household outbreak. We observed that the Y275 mutation was present as a minor variant in infected hosts before the onset of therapy. We also found evidence for the transmission of this drug-resistant variant with drug-susceptible viruses. These observations provide important information on the relative fitness of the Y275 mutation in the absence of oseltamivir treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available